BCR, not TCR, repertoire diversity is associated with favorable COVID-19 prognosis

BCR(而非 TCR)库多样性与 COVID-19 的良好预后相关

阅读:14
作者:Faith Jessica Paran #, Rieko Oyama #, Abdullah Khasawneh, Tomohiko Ai, Hendra Saputra Ismanto, Aalaa Alrahman Sherif, Dianita Susilo Saputri, Chikako Ono, Mizue Saita, Satomi Takei, Yuki Horiuchi, Ken Yagi, Yoshiharu Matsuura, Yasushi Okazaki, Kazuhisa Takahashi, Daron M Standley, Yoko Tabe, Toshio

Conclusion

This study underscores that BCR repertoire diversity, but not TCR diversity, correlates with favorable outcomes in COVID-19.

Methods

In this study, we used single-cell RNA sequencing to analyze the immune responses in recovered and deceased COVID-19 patients during moderate and critical stages.

Results

Expanded T cell receptor (TCR) clones were predominantly SARS-CoV-2-specific, but represented only a small fraction of the total repertoire in all patients. In contrast, while deceased patients exhibited monoclonal B cell receptor (BCR) expansions without COVID-19 specificity, survivors demonstrated diverse and specific BCR clones. These findings suggest that neither TCR diversity nor BCR monoclonal expansions are sufficient for viral clearance and subsequent recovery. Differential gene expression analysis revealed that protein biosynthetic processes were enriched in survivors, but that potentially damaging mitochondrial ATP metabolism was activated in the deceased.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。